



Sunovion Pharmaceuticals Inc.

84 Waverling Drive, Marlborough, MA 01752-7077
Tel: 908-351-8700 | Fax: 908-357-7490

July 6, 2020

Office of Pharmacy Affairs (OPA)
Health Resources and Services Administration (HRSA)
Department of Health and Human Services (HHS)
5600 Fishers Lane, Parklawn Building, Mail Stop 10C-03
Rockville, Maryland 20857

Sunovion Pharmaceuticals, Inc. Limited Distribution Network for KYNMOBI™ (apomorphine hydrochloride)

This notice provides information to eligible 340B covered entities about how to acquire KYNMOBI™ (apomorphine hydrochloride) at the calculated 340B ceiling price. KYNMOBI™ (apomorphine hydrochloride) is indicated to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson's disease.

Product Name/Strength	NDC
KYNMOBI™ (apomorphine hydrochloride) 10 mg	63402-010-30
KYNMOBI™ (apomorphine hydrochloride) 15 mg	63402-015-30
KYNMOBI™ (apomorphine hydrochloride) 20 mg	63402-020-30
KYNMOBI™ (apomorphine hydrochloride) 25 mg	63402-025-30
KYNMOBI™ (apomorphine hydrochloride) 30 mg	63402-030-30

Sunovion operates a limited distribution network composed of three (3) specialty distributors. This network was established to ensure the appropriate, consistent, and efficient delivery of our medicine to patients with Parkinson's disease as well as guarantee broad access to our medicines. Eligible 340B covered entities looking to purchase Sunovion's KYNMOBI™, please contact one of Sunovion's network specialty distributor partners:

Specialty Distributors

McKesson Plasma and Biologics LLC
DMS Pharmaceutical Group, Inc.
Anda Incorporated

Sunovion takes both its obligations to protect patient safety and under the 340B program seriously and works to ensure that KYNMOBI™ is available to 340B covered entities in a manner that is no more restrictive than it is for non-340B entities. If you have any questions about this plan or experience any difficulty obtaining KYNMOBI™ at the prevailing 340B ceiling price for your eligible patients, please contact Brent Oakleaf at brent.oakleaf@sunovion.com. Please feel free to share this letter and the information contained herein with 340B covered entities and other interested parties as you deem appropriate.